Faeth Therapeutics, a clinical-stage biotechnology company advancing therapies that systematically target tumor metabolism, ...
The new funds will allow the company to test its multi-node PI3K treatment approach in a new endometrial cancer trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback